Turns Out That Biosimilars Do Impact Biologic Drug Costs

(MedPage Today) -- Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these products -- even though biosimilars...